Wrap Text
Notification: transactions by persons discharging managerial responsibilities & persons closely associated with them
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)
5 August 2022
NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out the details of awards over ordinary shares in Mediclinic (‘Shares’) granted to
directors and other persons discharging managerial responsibilities (‘PDMRs’) on 5 August 2022 under
the Company’s short-term incentive scheme (‘STI’) and long-term incentive plan (‘LTIP’), in accordance
with the Remuneration Policy and share plan rules approved by shareholders at the annual general
meeting of the Company held on 28 July 2022.
Name Director/ Number of Number of Shares
PDMR Shares awarded under
awarded the LTIP
under the STI
Dr Carel Aron van der Merwe Director 74 718 237 716
Petrus Jurgens Myburgh Director 47 488 148 319
David John Hadley PDMR n/a 58 369
Gert Cornelis Hattingh PDMR n/a 28 716
Dr Dirk Cornelius le Roux PDMR n/a 22 450
Dr Daniel Liedtke PDMR n/a 52 074
Magnus Oetiker PDMR n/a 51 945
Koert Hendrik Stefanus Pretorius PDMR n/a 30 055
Dr René Toua PDMR n/a 23 594
Dr Tyson Bruno Welzel PDMR n/a 40 608
Greg van Wyk PDMR n/a 27 270
The above awards were granted for nil consideration and are based on the closing price of a Share on
4 August 2022, which equates to £4.98 per Share.
1. Details of PDMR / person closely associated with them
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Group Chief Executive Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4.1 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Short-Term Incentive scheme
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 74 718
d) Aggregated
information
Aggregated volume 74 718
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
4.2 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 237 716
d) Aggregated
information
Aggregated volume 237 716
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Group Chief Financial Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4.1 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Short-Term Incentive scheme
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 47 488
d) Aggregated
information
Aggregated volume 47 488
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
4.2 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 148 319
d) Aggregated
information
Aggregated volume 148 319
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name David John Hadley
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Middle East
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 58 369
d) Aggregated
information
Aggregated volume 58 369
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Gert Cornelis Hattingh
2. Reason for the notification
a) Position / status Group Chief Governance Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 28 716
d) Aggregated
information
Aggregated volume 28 716
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Dr Dirk Cornelius le Roux
2. Reason for the notification
a) Position / status Group Chief Information Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 22 450
d) Aggregated
information
Aggregated volume 22 450
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Dr Daniel Liedtke
2. Reason for the notification
a) Position / status Chief Executive Officer: Hirslanden
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 52 074
d) Aggregated
information
Aggregated volume 52 074
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Magnus Oetiker
2. Reason for the notification
a) Position / status Group Chief Strategy Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 51 945
d) Aggregated
information
Aggregated volume 51 945
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Koert Hendrik Stefanus Pretorius
2. Reason for the notification
a) Position / status Group Chief Operating Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 30 055
d) Aggregated
information
Aggregated volume 30 055
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Dr René Toua
2. Reason for the notification
a) Position / status Group Chief Clinical Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 23 594
d) Aggregated
information
Aggregated volume 23 594
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Dr Tyson Bruno Welzel
2. Reason for the notification
a) Position / status Group Chief Innovation Officer – Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 40 608
d) Aggregated
information
Aggregated volume 40 608
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / person closely associated with them
a) Name Greg van Wyk
2. Reason for the notification
a) Position / status Chief Executive Officer: Mediclinic Southern Africa
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Award over ordinary shares in Mediclinic International plc granted at
transaction nil cost under the Company’s Long-Term Incentive Plan
c) Price(s) and Price(s) Volume(s)
volume(s) £nil 27 270
d) Aggregated
information
Aggregated volume 27 270
Price £nil
e) Date of the 5 August 2022
transaction
f) Place of the Outside a trading venue
transaction
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day
case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three
of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four
of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle
East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient
beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital
in the Kingdom of Saudi Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 05-08-2022 04:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
